Palantir’s Latest Contract Is Very Good News for PLTR Stock

InvestorPlace2022-05-06

Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

109

Report

Comment（22）

tigernaut
·2022-05-07
👍
Reply
Like
Report
Hangen
·2022-05-06
They need to solve the root of the problem... Stop share dilution and earn profit!
Reply
2
Report
LB881
·2022-05-06
[Strong]
Reply
1
Report
blessed_1
·2022-05-06
Thanks
Reply
Like
Report
Selivtamil
·2022-05-06
👍
Reply
2
Report
Cheryi
·2022-05-06
Ok
Reply
Like
Report
LEESIMON
·2022-05-06
Great
Reply
Like
Report
Toby_Chua
·2022-05-06
Still waiting for $5 entry point
Reply
1
Report
Asphen
·2022-05-06
Won't move much
Reply
1
Report
Victorhc88
·2022-05-06
Like
Reply
1
Report
BlueDaisy
·2022-05-06
Need bigger deals
Reply
2
Report
blessed_1
·2022-05-06
Thanks
Reply
Like
Report
STtee
·2022-05-06
Woah woah finally some exciting news for palantir!
Reply
4
Report
ZJ0429
·2022-05-06
po
Reply
3
Report
TradingVest
·2022-05-06
Cool
Reply
5
Report
twm124
·2022-05-06
Nice
Reply
2
Report
breAkdaWn
·2022-05-06
its good news for Palantir.. managers. they can get bonus. for shareholders . nothing is changed
Reply
5
Report
慢的老人
·2022-05-06
Looking forward to next week's financial results release by $Palantir Technologies Inc.(PLTR)$. They are still overly reliant on US govt contracts and there are not enough private sector clients.
Reply
7
Report
TeslaTTM
·2022-05-06
We need this. Pls soar. TTM!
Reply
3
Report
SGboy
·2022-05-06
Good news?
Reply
3
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1153316571?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-05-06 10:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153316571","market":"us","top_or_hot":-1,"title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","media":"InvestorPlace","content":"<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Source Link</a>\n\n</div>\n","source":"lsy1606302653667","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PLTR","symbol_name":"Palantir Technologies Inc.","start_time":0,"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","article_id":"1153316571","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","pubTimestamp":1651804011,"sourceInfo":{"source_id":"lsy1606302653667","name":"InvestorPlace"},"weMediaInfo":null,"summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"translate_title":"Palantir的最新合同对PLTR股票来说是一个非常好的消息","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLTR":0.9},"content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9066351437,"gmtCreate":1651853117529,"gmtModify":1676534984687,"author":{"id":"3567239827558758","authorId":"3567239827558758","name":"tigernaut","avatar":"https://static.tigerbbs.com/66e331c670eb88443b88c6bdb76224cf","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":3,"crmLevelSwitch":1,"idStr":"3567239827558758","authorIdStr":"3567239827558758"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9066351437","repostId":1153316571,"repostType":2,"repost":{"id":"1153316571","pubTimestamp":1651804011,"share":"https://ttm.financial/m/news/1153316571?lang=&edition=fundamental","pubTime":"2022-05-06 10:26","market":"us","language":"en","title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","media":"InvestorPlace","summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","content":"<html><head></head><body><p><b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.</p><p>“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”</p><p>Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.</p><p>It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.</p><p>The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.</p><p>Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.</p><p>At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.</p><p>The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.</p><p>The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.</p><p>I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.</p><p>PLTR stock remains a long-term buy for aggressive investors only.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153316571","content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9066323599,"gmtCreate":1651851590411,"gmtModify":1676534984435,"author":{"id":"4087724962016220","authorId":"4087724962016220","name":"Hangen","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"4087724962016220","authorIdStr":"4087724962016220"},"htmlText":"They need to solve the root of the problem... Stop share dilution and earn profit!","listText":"They need to solve the root of the problem... Stop share dilution and earn profit!","text":"They need to solve the root of the problem... Stop share dilution and earn profit!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9066323599","repostId":1153316571,"repostType":2,"repost":{"id":"1153316571","pubTimestamp":1651804011,"share":"https://ttm.financial/m/news/1153316571?lang=&edition=fundamental","pubTime":"2022-05-06 10:26","market":"us","language":"en","title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","media":"InvestorPlace","summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","content":"<html><head></head><body><p><b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.</p><p>“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”</p><p>Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.</p><p>It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.</p><p>The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.</p><p>Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.</p><p>At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.</p><p>The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.</p><p>The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.</p><p>I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.</p><p>PLTR stock remains a long-term buy for aggressive investors only.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153316571","content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9066971588,"gmtCreate":1651845429144,"gmtModify":1676534982467,"author":{"id":"4099373918785850","authorId":"4099373918785850","name":"LB881","avatar":"https://static.tigerbbs.com/0c0a14e9e40680c3c7f68874b617b7e9","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":5,"crmLevelSwitch":1,"idStr":"4099373918785850","authorIdStr":"4099373918785850"},"htmlText":"[Strong]&nbsp;","listText":"[Strong]&nbsp;","text":"[Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9066971588","repostId":1153316571,"repostType":4,"repost":{"id":"1153316571","pubTimestamp":1651804011,"share":"https://ttm.financial/m/news/1153316571?lang=&edition=fundamental","pubTime":"2022-05-06 10:26","market":"us","language":"en","title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","media":"InvestorPlace","summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","content":"<html><head></head><body><p><b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.</p><p>“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”</p><p>Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.</p><p>It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.</p><p>The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.</p><p>Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.</p><p>At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.</p><p>The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.</p><p>The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.</p><p>I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.</p><p>PLTR stock remains a long-term buy for aggressive investors only.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153316571","content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9066074889,"gmtCreate":1651829903641,"gmtModify":1676534979811,"author":{"id":"4112410321254552","authorId":"4112410321254552","name":"blessed_1","avatar":"https://community-static.tradeup.com/news/71622697830d9517eb67a61917d8a95f","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":4,"crmLevelSwitch":1,"idStr":"4112410321254552","authorIdStr":"4112410321254552"},"htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9066074889","repostId":1153316571,"repostType":2,"repost":{"id":"1153316571","pubTimestamp":1651804011,"share":"https://ttm.financial/m/news/1153316571?lang=&edition=fundamental","pubTime":"2022-05-06 10:26","market":"us","language":"en","title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","media":"InvestorPlace","summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","content":"<html><head></head><body><p><b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.</p><p>“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”</p><p>Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.</p><p>It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.</p><p>The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.</p><p>Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.</p><p>At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.</p><p>The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.</p><p>The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.</p><p>I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.</p><p>PLTR stock remains a long-term buy for aggressive investors only.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153316571","content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9066034816,"gmtCreate":1651817665335,"gmtModify":1676534977510,"author":{"id":"4113984386762092","authorId":"4113984386762092","name":"Selivtamil","avatar":"https://community-static.tradeup.com/news/9484f4baf16444c5b51ba635248b013d","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4113984386762092","authorIdStr":"4113984386762092"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9066034816","repostId":1153316571,"repostType":4,"repost":{"id":"1153316571","pubTimestamp":1651804011,"share":"https://ttm.financial/m/news/1153316571?lang=&edition=fundamental","pubTime":"2022-05-06 10:26","market":"us","language":"en","title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","media":"InvestorPlace","summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","content":"<html><head></head><body><p><b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.</p><p>“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”</p><p>Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.</p><p>It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.</p><p>The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.</p><p>Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.</p><p>At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.</p><p>The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.</p><p>The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.</p><p>I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.</p><p>PLTR stock remains a long-term buy for aggressive investors only.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153316571","content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":616507883,"gmtCreate":1651815812642,"gmtModify":1676533068493,"author":{"id":"3568940106394782","authorId":"3568940106394782","name":"Cheryi","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3568940106394782","authorIdStr":"3568940106394782"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/616507883","repostId":1153316571,"repostType":4,"repost":{"id":"1153316571","pubTimestamp":1651804011,"share":"https://ttm.financial/m/news/1153316571?lang=&edition=fundamental","pubTime":"2022-05-06 10:26","market":"us","language":"en","title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","media":"InvestorPlace","summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","content":"<html><head></head><body><p><b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.</p><p>“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”</p><p>Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.</p><p>It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.</p><p>The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.</p><p>Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.</p><p>At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.</p><p>The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.</p><p>The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.</p><p>I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.</p><p>PLTR stock remains a long-term buy for aggressive investors only.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153316571","content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":9068749545,"gmtCreate":1651810620087,"gmtModify":1676534976213,"author":{"id":"3579044609497336","authorId":"3579044609497336","name":"LEESIMON","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":8,"crmLevelSwitch":1,"idStr":"3579044609497336","authorIdStr":"3579044609497336"},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9068749545","repostId":1153316571,"repostType":4,"repost":{"id":"1153316571","pubTimestamp":1651804011,"share":"https://ttm.financial/m/news/1153316571?lang=&edition=fundamental","pubTime":"2022-05-06 10:26","market":"us","language":"en","title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","media":"InvestorPlace","summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","content":"<html><head></head><body><p><b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.</p><p>“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”</p><p>Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.</p><p>It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.</p><p>The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.</p><p>Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.</p><p>At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.</p><p>The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.</p><p>The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.</p><p>I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.</p><p>PLTR stock remains a long-term buy for aggressive investors only.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153316571","content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9068786483,"gmtCreate":1651806761642,"gmtModify":1676534975262,"author":{"id":"3576326749731922","authorId":"3576326749731922","name":"Toby_Chua","avatar":"https://community-static.tradeup.com/news/82ec063fd73ccbceee82eab015cdf3fd","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":7,"crmLevelSwitch":1,"idStr":"3576326749731922","authorIdStr":"3576326749731922"},"htmlText":"Still waiting for $5 entry point","listText":"Still waiting for $5 entry point","text":"Still waiting for $5 entry point","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9068786483","repostId":1153316571,"repostType":4,"repost":{"id":"1153316571","pubTimestamp":1651804011,"share":"https://ttm.financial/m/news/1153316571?lang=&edition=fundamental","pubTime":"2022-05-06 10:26","market":"us","language":"en","title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","media":"InvestorPlace","summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","content":"<html><head></head><body><p><b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.</p><p>“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”</p><p>Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.</p><p>It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.</p><p>The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.</p><p>Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.</p><p>At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.</p><p>The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.</p><p>The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.</p><p>I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.</p><p>PLTR stock remains a long-term buy for aggressive investors only.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153316571","content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9068789228,"gmtCreate":1651806334564,"gmtModify":1676534975148,"author":{"id":"3576339097425722","authorId":"3576339097425722","name":"Asphen","avatar":"https://community-static.tradeup.com/news/55ff1b64b2787933c17d863ecae83f09","vip":1,"crmLevel":8,"crmLevelSwitch":1,"idStr":"3576339097425722","authorIdStr":"3576339097425722"},"htmlText":"Won't move much&nbsp;","listText":"Won't move much&nbsp;","text":"Won't move much","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9068789228","repostId":1153316571,"repostType":4,"repost":{"id":"1153316571","pubTimestamp":1651804011,"share":"https://ttm.financial/m/news/1153316571?lang=&edition=fundamental","pubTime":"2022-05-06 10:26","market":"us","language":"en","title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","media":"InvestorPlace","summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","content":"<html><head></head><body><p><b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.</p><p>“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”</p><p>Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.</p><p>It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.</p><p>The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.</p><p>Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.</p><p>At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.</p><p>The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.</p><p>The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.</p><p>I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.</p><p>PLTR stock remains a long-term buy for aggressive investors only.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153316571","content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9068715675,"gmtCreate":1651806093497,"gmtModify":1676534975082,"author":{"id":"3582248650466523","authorId":"3582248650466523","name":"Victorhc88","avatar":"https://static.tigerbbs.com/d72a1d9498132424b1eddb4db3c77265","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582248650466523","authorIdStr":"3582248650466523"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9068715675","repostId":1153316571,"repostType":4,"repost":{"id":"1153316571","pubTimestamp":1651804011,"share":"https://ttm.financial/m/news/1153316571?lang=&edition=fundamental","pubTime":"2022-05-06 10:26","market":"us","language":"en","title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","media":"InvestorPlace","summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","content":"<html><head></head><body><p><b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.</p><p>“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”</p><p>Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.</p><p>It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.</p><p>The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.</p><p>Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.</p><p>At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.</p><p>The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.</p><p>The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.</p><p>I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.</p><p>PLTR stock remains a long-term buy for aggressive investors only.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153316571","content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9068711664,"gmtCreate":1651805738158,"gmtModify":1676534974990,"author":{"id":"3582677971530678","authorId":"3582677971530678","name":"BlueDaisy","avatar":"https://static.tigerbbs.com/0747094283743978b62fb8b1ee2cf44c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582677971530678","authorIdStr":"3582677971530678"},"htmlText":"Need bigger deals&nbsp;","listText":"Need bigger deals&nbsp;","text":"Need bigger deals","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9068711664","repostId":1153316571,"repostType":4,"repost":{"id":"1153316571","pubTimestamp":1651804011,"share":"https://ttm.financial/m/news/1153316571?lang=&edition=fundamental","pubTime":"2022-05-06 10:26","market":"us","language":"en","title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","media":"InvestorPlace","summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","content":"<html><head></head><body><p><b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.</p><p>“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”</p><p>Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.</p><p>It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.</p><p>The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.</p><p>Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.</p><p>At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.</p><p>The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.</p><p>The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.</p><p>I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.</p><p>PLTR stock remains a long-term buy for aggressive investors only.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153316571","content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9068713787,"gmtCreate":1651805681349,"gmtModify":1676534974982,"author":{"id":"4112410321254552","authorId":"4112410321254552","name":"blessed_1","avatar":"https://community-static.tradeup.com/news/71622697830d9517eb67a61917d8a95f","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":4,"crmLevelSwitch":1,"idStr":"4112410321254552","authorIdStr":"4112410321254552"},"htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9068713787","repostId":1153316571,"repostType":2,"repost":{"id":"1153316571","pubTimestamp":1651804011,"share":"https://ttm.financial/m/news/1153316571?lang=&edition=fundamental","pubTime":"2022-05-06 10:26","market":"us","language":"en","title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","media":"InvestorPlace","summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","content":"<html><head></head><body><p><b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.</p><p>“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”</p><p>Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.</p><p>It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.</p><p>The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.</p><p>Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.</p><p>At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.</p><p>The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.</p><p>The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.</p><p>I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.</p><p>PLTR stock remains a long-term buy for aggressive investors only.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153316571","content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9068710526,"gmtCreate":1651805342465,"gmtModify":1676534974926,"author":{"id":"3573295814526662","authorId":"3573295814526662","name":"STtee","avatar":"https://static.tigerbbs.com/2f8b6d27a66090fbddbc0ceedceb166a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3573295814526662","authorIdStr":"3573295814526662"},"htmlText":"Woah woah finally some exciting news for palantir!","listText":"Woah woah finally some exciting news for palantir!","text":"Woah woah finally some exciting news for palantir!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9068710526","repostId":1153316571,"repostType":2,"repost":{"id":"1153316571","pubTimestamp":1651804011,"share":"https://ttm.financial/m/news/1153316571?lang=&edition=fundamental","pubTime":"2022-05-06 10:26","market":"us","language":"en","title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","media":"InvestorPlace","summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","content":"<html><head></head><body><p><b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.</p><p>“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”</p><p>Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.</p><p>It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.</p><p>The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.</p><p>Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.</p><p>At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.</p><p>The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.</p><p>The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.</p><p>I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.</p><p>PLTR stock remains a long-term buy for aggressive investors only.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153316571","content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9068710119,"gmtCreate":1651805314231,"gmtModify":1676534974942,"author":{"id":"3575944618458188","authorId":"3575944618458188","name":"ZJ0429","avatar":"https://static.tigerbbs.com/cf7036ebe7fa36be18d7ae7011969bab","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3575944618458188","authorIdStr":"3575944618458188"},"htmlText":"po","listText":"po","text":"po","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9068710119","repostId":1153316571,"repostType":4,"repost":{"id":"1153316571","pubTimestamp":1651804011,"share":"https://ttm.financial/m/news/1153316571?lang=&edition=fundamental","pubTime":"2022-05-06 10:26","market":"us","language":"en","title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","media":"InvestorPlace","summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","content":"<html><head></head><body><p><b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.</p><p>“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”</p><p>Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.</p><p>It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.</p><p>The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.</p><p>Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.</p><p>At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.</p><p>The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.</p><p>The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.</p><p>I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.</p><p>PLTR stock remains a long-term buy for aggressive investors only.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153316571","content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9068737175,"gmtCreate":1651805141797,"gmtModify":1676534974878,"author":{"id":"3575328629727225","authorId":"3575328629727225","name":"TradingVest","avatar":"https://static.tigerbbs.com/3055a5262208b8d6fdb51c32c0b5aa1e","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":4,"crmLevelSwitch":0,"idStr":"3575328629727225","authorIdStr":"3575328629727225"},"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9068737175","repostId":1153316571,"repostType":4,"repost":{"id":"1153316571","pubTimestamp":1651804011,"share":"https://ttm.financial/m/news/1153316571?lang=&edition=fundamental","pubTime":"2022-05-06 10:26","market":"us","language":"en","title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","media":"InvestorPlace","summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","content":"<html><head></head><body><p><b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.</p><p>“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”</p><p>Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.</p><p>It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.</p><p>The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.</p><p>Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.</p><p>At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.</p><p>The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.</p><p>The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.</p><p>I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.</p><p>PLTR stock remains a long-term buy for aggressive investors only.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153316571","content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9068737949,"gmtCreate":1651805113681,"gmtModify":1676534974886,"author":{"id":"4103447123846720","authorId":"4103447123846720","name":"twm124","avatar":"https://community-static.tradeup.com/news/133c111c9a6cf675442b0a95780a91d0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4103447123846720","authorIdStr":"4103447123846720"},"htmlText":"Nice&nbsp;","listText":"Nice&nbsp;","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9068737949","repostId":1153316571,"repostType":2,"repost":{"id":"1153316571","pubTimestamp":1651804011,"share":"https://ttm.financial/m/news/1153316571?lang=&edition=fundamental","pubTime":"2022-05-06 10:26","market":"us","language":"en","title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","media":"InvestorPlace","summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","content":"<html><head></head><body><p><b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.</p><p>“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”</p><p>Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.</p><p>It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.</p><p>The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.</p><p>Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.</p><p>At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.</p><p>The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.</p><p>The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.</p><p>I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.</p><p>PLTR stock remains a long-term buy for aggressive investors only.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153316571","content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9068735501,"gmtCreate":1651804908503,"gmtModify":1676534974855,"author":{"id":"3569809505691000","authorId":"3569809505691000","name":"breAkdaWn","avatar":"https://community-static.tradeup.com/news/4c3676c14de9bfcd6f45bcf7ba4ddb6c","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3569809505691000","authorIdStr":"3569809505691000"},"htmlText":"its good news for Palantir.. managers. they can get &nbsp;bonus. for shareholders . nothing is changed","listText":"its good news for Palantir.. managers. they can get &nbsp;bonus. for shareholders . nothing is changed","text":"its good news for Palantir.. managers. they can get bonus. for shareholders . nothing is changed","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9068735501","repostId":1153316571,"repostType":2,"repost":{"id":"1153316571","pubTimestamp":1651804011,"share":"https://ttm.financial/m/news/1153316571?lang=&edition=fundamental","pubTime":"2022-05-06 10:26","market":"us","language":"en","title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","media":"InvestorPlace","summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","content":"<html><head></head><body><p><b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.</p><p>“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”</p><p>Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.</p><p>It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.</p><p>The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.</p><p>Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.</p><p>At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.</p><p>The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.</p><p>The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.</p><p>I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.</p><p>PLTR stock remains a long-term buy for aggressive investors only.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153316571","content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9068735211,"gmtCreate":1651804881633,"gmtModify":1676534974854,"author":{"id":"3582028884093480","authorId":"3582028884093480","name":"慢的老人","avatar":"https://static.tigerbbs.com/d8809bb976396889eb133162af0901b8","vip":1,"crmLevel":3,"crmLevelSwitch":1,"idStr":"3582028884093480","authorIdStr":"3582028884093480"},"htmlText":"Looking forward to next week's financial results release by&nbsp;<a href=\"https://ttm.financial/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>. They are still overly&nbsp;reliant on US govt contracts and there are not enough private sector clients.","listText":"Looking forward to next week's financial results release by&nbsp;<a href=\"https://ttm.financial/S/PLTR\">$Palantir Technologies Inc.(PLTR)$</a>. They are still overly&nbsp;reliant on US govt contracts and there are not enough private sector clients.","text":"Looking forward to next week's financial results release by $Palantir Technologies Inc.(PLTR)$. They are still overly reliant on US govt contracts and there are not enough private sector clients.","images":[],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9068735211","repostId":1153316571,"repostType":4,"repost":{"id":"1153316571","pubTimestamp":1651804011,"share":"https://ttm.financial/m/news/1153316571?lang=&edition=fundamental","pubTime":"2022-05-06 10:26","market":"us","language":"en","title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","media":"InvestorPlace","summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","content":"<html><head></head><body><p><b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.</p><p>“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”</p><p>Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.</p><p>It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.</p><p>The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.</p><p>Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.</p><p>At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.</p><p>The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.</p><p>The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.</p><p>I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.</p><p>PLTR stock remains a long-term buy for aggressive investors only.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153316571","content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9068735116,"gmtCreate":1651804853335,"gmtModify":1676534974839,"author":{"id":"3572861472613031","authorId":"3572861472613031","name":"TeslaTTM","avatar":"https://static.tigerbbs.com/8365e0e3f1bed08885c0c201c5f7fb19","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3572861472613031","authorIdStr":"3572861472613031"},"htmlText":"We need this. Pls soar. TTM!","listText":"We need this. Pls soar. TTM!","text":"We need this. Pls soar. TTM!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9068735116","repostId":1153316571,"repostType":2,"repost":{"id":"1153316571","pubTimestamp":1651804011,"share":"https://ttm.financial/m/news/1153316571?lang=&edition=fundamental","pubTime":"2022-05-06 10:26","market":"us","language":"en","title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","media":"InvestorPlace","summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","content":"<html><head></head><body><p><b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.</p><p>“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”</p><p>Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.</p><p>It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.</p><p>The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.</p><p>Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.</p><p>At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.</p><p>The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.</p><p>The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.</p><p>I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.</p><p>PLTR stock remains a long-term buy for aggressive investors only.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153316571","content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9068732655,"gmtCreate":1651804703677,"gmtModify":1676534974823,"author":{"id":"4093688471950400","authorId":"4093688471950400","name":"SGboy","avatar":"https://static.tigerbbs.com/53fad8dabfd576c90fe8050483aa504f","vip":1,"crmLevel":7,"crmLevelSwitch":1,"idStr":"4093688471950400","authorIdStr":"4093688471950400"},"htmlText":"Good news?","listText":"Good news?","text":"Good news?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9068732655","repostId":1153316571,"repostType":4,"repost":{"id":"1153316571","pubTimestamp":1651804011,"share":"https://ttm.financial/m/news/1153316571?lang=&edition=fundamental","pubTime":"2022-05-06 10:26","market":"us","language":"en","title":"Palantir’s Latest Contract Is Very Good News for PLTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1153316571","media":"InvestorPlace","summary":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department o","content":"<html><head></head><body><p><b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.</p><p>“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”</p><p>Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.</p><p>It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.</p><p>The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.</p><p>Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.</p><p>At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.</p><p>The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.</p><p>The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.</p><p>I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.</p><p>PLTR stock remains a long-term buy for aggressive investors only.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir’s Latest Contract Is Very Good News for PLTR Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir’s Latest Contract Is Very Good News for PLTR Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-06 10:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) ...</p>\n\n<a href=\"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2022/05/palantirs-latest-contract-is-very-good-news-for-pltr-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153316571","content_text":"Palantir(NYSE:PLTR) announced on May 4 that it received a $90-million contract from the Department of Health and Human Services (HHS). The federal department’s 5-year blanket purchase agreement (BPA) is excellent news for PLTR stock.“We are grateful for our continued partnership with HHS and the confidence in our software it is showing by selecting Palantir for a long-term, wide-ranging BPA,” said Akash Jain, president of Palantir USG. “We are proud to provide the software backbone to some of the country’s most critical public health missions.”Palantir’s made several moves to grow its healthcare business in recent months. Yesterday’s announcement indicates that the data analytics software company is on the right track to increasing healthcare revenues.It started in mid-April when the National Health Service England (NHSE) announced that it would develop a 240 million British Pounds($298 million) federated data platform (FDP) to allow multiple NHS databases to function as one.The contract itself has two parts. The first is the FDP platform itself. The second is to provide the privacy-enhancing technology necessary to enable the platform to be effective while protecting patient confidentiality.Palantir, which already has a working relationship with the NHSE, is widely believed to be the frontrunner for the contract.At the end of March, the NHSX director of artificial intelligence (AI), Indra Joshi, left the UK government’s healthcare agency to join Palantir. Joshi ran the NHS AI Lab, which is charged with integrating AI technologies into the country’s healthcare system. She will work in Palantir’s UK unit, helping customers use AI to transform their businesses.The latest news suggests aggressive investors might take an initial position. PLTR stock appears ready to go on a run. Down almost 43% year-t0-date, a move higher would be a welcome sight nearing the halfway point in 2022.The share price appears to provide very healthy support at $10.50. On three occasions in 2022, it’s tested this level. On each occasion, it’s rebounded off that support line.I continue to like Palantir despite the fact it’s having trouble generating a profit. However, if its healthcare business is any indication, patient investors should be rewarded soon enough.PLTR stock remains a long-term buy for aggressive investors only.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":109,"commentSize":22,"repostSize":0,"favoriteSize":2,"likeStatus":false,"favoriteStatus":false}}